Global /Australia /Healthcare /Drug Manufacturers - General /ILA

Island Pharmaceuticals Ltd.

ILA

• ASX: ILA • Delayed

0.3750AUD -3.9%

0.2641 USD

As of 6 June 2026, Island Pharmaceuticals Ltd. has a market cap of $82.27M USD, ranking #26939 globally and #636 in Australia. It ranks #2419 in the Healthcare sector, and #872 in the Drug Manufacturers - General industry.

Global Rank

26939

Country Rank

636

Sector Rank

2419

Industry Rank

872

Key Stats

Market Cap

$82.27MUSD

115.28M AUD

Enterprise Value

$76.36MUSD

108.41M AUD

Revenue (TTM)

$44.85KUSD

62.85K AUD

Net Income (TTM)

-$5.14MUSD

-7.2M AUD

PS Ratio

1834.1

PB Ratio

16.1

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

David Foster open_in_new

Founded

2017

Website

islandpharmaceuticals.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.9%	2.6%	5.4%	-12%	2.6%	-9.3%	169%	394%	-9.3%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	ILA Island Pharmaceuticals Ltd ISIN: AU0000138869 TV: TradingView: ASX: ILA SA: Stock Analysis: ASX: ILA YF: Yahoo Finance: ILA.AX GF: Google Finance: ASX: ILA BA: Barron's: ILA MS: Morningstar: XASX: ILA	0.3750 AUD	TV: TradingView: ASX: ILA SA: Stock Analysis: ASX: ILA YF: Yahoo Finance: ILA.AX GF: Google Finance: ASX: ILA BA: Barron's: ILA MS: Morningstar: XASX: ILA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Island Pharmaceuticals Ltd.

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 28K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 1K%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 321%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 308%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 163%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 102%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 926K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 665K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 438K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 395K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 352K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 337K%	20.5	Switzerland

chevron_leftBack